肺癌骨转移病例讨论(规范用药)594.pptVIP

* * Zoledronic Acid Reduced the Risk of Developing an SRE Treatment with 4 mg zoledronic acid significantly reduced the risk of developing an SRE by 31% compared with placebo (hazard ratio = 0.693; 95% confidence interval [CI] = 0.542, 0.886; P = .003) Multiple event analysis provides a sensitive measure of skeletal morbidity because it accounts for all events as well as the time between events The hazard ratio reflects the risk of experiencing an SRE between 2 treatment groups; a hazard ratio of 1 indicates a decreased risk for patients treated with 4 mg zoledronic acid. If the upper boun